Merck (MRK) Other financing activities (2009 - 2026)
Merck (MRK) reported Other financing activities of -$80.0 million for Q1 2026, down 33.33% year-over-year from -$120.0 million in Q1 2025, and down 166.12% on a QoQ basis from $121.0 million in Q4 2025.
Merck (MRK) has 18 years of Other financing activities data on file, last reported at -$80.0 million in Q1 2026.
- Quarterly Other financing activities fell 33.33% year-over-year to -$80.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$151.0 million (up 57.34% YoY) and the FY2025 annual result came in at -$131.0 million, up 64.78% from the prior year.
- Other financing activities fell to -$80.0 million in Q1 2026 per MRK's latest filing, from $121.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $121.0 million in Q4 2025 and bottomed at -$234.0 million in Q2 2023.
- The 5-year median for Other financing activities is -$68.0 million (2022), against an average of -$67.7 million.
- The widest annual swing landed in 2024, when Other financing activities tumbled 1300.0%; it then jumped 388.1% in 2025.
- Tracing MRK's Other financing activities over 5 years: stood at -$68.0 million in 2022, then soared by 95.59% to -$3.0 million in 2023, then plunged by 1300.0% to -$42.0 million in 2024, then surged by 388.1% to $121.0 million in 2025, then slumped by 166.12% to -$80.0 million in 2026.
- Per Business Quant, the three latest MRK Other financing activities figures stand at -$80.0 million (Q1 2026), $121.0 million (Q4 2025), and $2.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -80.00 Mn |
| Mar 31, 2026 | -80.00 Mn |
| Dec 31, 2025 | 121.00 Mn |
| Dec 31, 2025 | 121.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -194.00 Mn |
| Jun 30, 2025 | -194.00 Mn |
| Mar 31, 2025 | -60.00 Mn |
| Mar 31, 2025 | -60.00 Mn |
| Dec 31, 2024 | -42.00 Mn |
| Dec 31, 2024 | -42.00 Mn |
| Sep 30, 2024 | -32.00 Mn |
| Sep 30, 2024 | -32.00 Mn |
| Jun 30, 2024 | -220.00 Mn |
| Jun 30, 2024 | -220.00 Mn |
| Mar 31, 2024 | -78.00 Mn |
| Mar 31, 2024 | -78.00 Mn |
| Dec 31, 2023 | -3.00 Mn |
| Dec 31, 2023 | -3.00 Mn |
| Sep 30, 2023 | -10.00 Mn |
| Sep 30, 2023 | -10.00 Mn |
| Jun 30, 2023 | -234.00 Mn |
| Jun 30, 2023 | -234.00 Mn |
| Mar 31, 2023 | -81.00 Mn |
| Mar 31, 2023 | -81.00 Mn |
| Dec 31, 2022 | -68.00 Mn |
| Dec 31, 2022 | -68.00 Mn |
| Sep 30, 2022 | 35.00 Mn |
| Sep 30, 2022 | 35.00 Mn |
| Jun 30, 2022 | -104.00 Mn |
| Jun 30, 2022 | -104.00 Mn |
| Mar 31, 2022 | -103.00 Mn |
| Mar 31, 2022 | -103.00 Mn |
| Dec 31, 2021 | -33.00 Mn |
| Dec 31, 2021 | -33.00 Mn |
| Sep 30, 2021 | 251.00 Mn |
| Sep 30, 2021 | 251.00 Mn |
| Jun 30, 2021 | -407.00 Mn |
| Jun 30, 2021 | -407.00 Mn |
| Mar 31, 2021 | -97.00 Mn |
| Mar 31, 2021 | -97.00 Mn |
| Jun 30, 2020 | 316.00 Mn |
| Jun 30, 2020 | 316.00 Mn |
| Mar 31, 2020 | -316.00 Mn |
| Mar 31, 2020 | -316.00 Mn |
| Dec 31, 2019 | 240.00 Mn |
| Dec 31, 2019 | 240.00 Mn |
| Sep 30, 2019 | -33.00 Mn |
| Sep 30, 2019 | -33.00 Mn |
| Jun 30, 2019 | -115.00 Mn |
| Jun 30, 2019 | -115.00 Mn |
| Mar 31, 2019 | -92.00 Mn |
| Mar 31, 2019 | -92.00 Mn |
| Dec 31, 2018 | -36.00 Mn |
| Dec 31, 2018 | -36.00 Mn |
| Sep 30, 2018 | -12.00 Mn |
| Sep 30, 2018 | -12.00 Mn |
| Jun 30, 2018 | -194.00 Mn |
| Jun 30, 2018 | -194.00 Mn |
| Mar 31, 2018 | -83.00 Mn |
| Mar 31, 2018 | -83.00 Mn |
| Dec 31, 2017 | -28.00 Mn |
| Dec 31, 2017 | -28.00 Mn |
| Sep 30, 2017 | -81.00 Mn |
| Sep 30, 2017 | -81.00 Mn |
| Jun 30, 2017 | -63.00 Mn |
| Jun 30, 2017 | -63.00 Mn |
| Mar 31, 2017 | -23.00 Mn |
| Mar 31, 2017 | -23.00 Mn |
| Dec 31, 2016 | -9.00 Mn |
| Dec 31, 2016 | -9.00 Mn |
| Sep 30, 2016 | -8.00 Mn |
| Sep 30, 2016 | -8.00 Mn |
| Jun 30, 2016 | -76.00 Mn |
| Jun 30, 2016 | -76.00 Mn |
| Mar 31, 2016 | -25.00 Mn |
| Mar 31, 2016 | -25.00 Mn |
| Dec 31, 2015 | 2.00 Mn |
| Dec 31, 2015 | 2.00 Mn |
| Sep 30, 2015 | -44.00 Mn |
| Sep 30, 2015 | -44.00 Mn |
| Jun 30, 2015 | -11.00 Mn |
| Jun 30, 2015 | -11.00 Mn |
| Mar 31, 2015 | -8.00 Mn |
| Mar 31, 2015 | -8.00 Mn |
| Dec 31, 2014 | 7.00 Mn |
| Dec 31, 2014 | 7.00 Mn |
| Sep 30, 2014 | 23.00 Mn |
| Sep 30, 2014 | 23.00 Mn |
| Jun 30, 2014 | 49.00 Mn |
| Jun 30, 2014 | 49.00 Mn |
| Dec 31, 2013 | 121.00 Mn |
| Dec 31, 2013 | 121.00 Mn |
| Sep 30, 2013 | -58.00 Mn |
| Sep 30, 2013 | -58.00 Mn |
| Jun 30, 2013 | -2.00 Mn |
| Jun 30, 2013 | -2.00 Mn |
| Mar 31, 2013 | -1.00 Mn |
| Mar 31, 2013 | -1.00 Mn |
| Dec 31, 2012 | 140.00 Mn |
| Dec 31, 2012 | 140.00 Mn |
| Sep 30, 2012 | -51.00 Mn |
| Sep 30, 2012 | -51.00 Mn |
| Jun 30, 2012 | -2.00 Mn |
| Jun 30, 2012 | -2.00 Mn |
| Mar 31, 2012 | -1.00 Mn |
| Mar 31, 2012 | -1.00 Mn |
| Dec 31, 2011 | 39.00 Mn |
| Dec 31, 2011 | 39.00 Mn |
| Sep 30, 2011 | -4.00 Mn |
| Sep 30, 2011 | -4.00 Mn |
| Jun 30, 2011 | -220.00 Mn |
| Jun 30, 2011 | -220.00 Mn |
| Mar 31, 2011 | 163.00 Mn |
| Mar 31, 2011 | 163.00 Mn |
| Dec 31, 2010 | 85.00 Mn |
| Dec 31, 2010 | 85.00 Mn |
| Sep 30, 2010 | -76.00 Mn |
| Sep 30, 2010 | -76.00 Mn |
| Jun 30, 2010 | -53.00 Mn |
| Jun 30, 2010 | -53.00 Mn |
| Mar 31, 2010 | -62.00 Mn |
| Mar 31, 2010 | -62.00 Mn |
| Dec 31, 2009 | 59.40 Mn |
| Dec 31, 2009 | 59.40 Mn |
| Sep 30, 2009 | 62.00 Mn |
| Sep 30, 2009 | 62.00 Mn |
| Jun 30, 2009 | -154.40 Mn |
| Jun 30, 2009 | -154.40 Mn |
| Mar 31, 2009 | -93.00 Mn |
| Mar 31, 2009 | -93.00 Mn |